Quintiles is the world's leading provider of services and solutions to the pharmaceutical and biotech industries. At the heart of Quintiles' offering is the ability to conduct extremely complex drug testing procedures on a world-wide basis.

Since 2000, the company has been involved in 3,300 clinical trials in 50 countries with 170,000 investigative sites and more than 2.5 million patients.

Quintiles' value to its customers is illustrated by the fact it has played a role in developing or commercializing each of the world's top 30 best-selling drugs, and 9 of the top 10 best-selling biotech drugs.

3i's investment will help the company consolidate its leadership in the world's growth hotspots such as India and Eastern Europe.